The Cooper Companies, Inc. (COO) SEC Filings & Earnings Calls
EquiReason read 13 The Cooper Companies, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-09-09 — The Cooper Companies reported Q3 2026 results with net income of $432.8M (diluted EPS $2.24) vs $98.3M ($0.49) in prior year, driven by a $307.2M discrete tax benefit and improved .
Source: SEC EDGAR filings · figures as of 2026-07-31 · read by EquiReason
- Market cap
- 11.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Dec, in 39 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
9 Sep 202610-QThe Cooper Companies reported Q3 2026 results with net income of $432.8M (diluted EPS $2.24) vs $98.3M ($0.49) in prior year, driven by a $307.2M discrete tax benefit and improved operating performance, partially offset by a $272.0M litigatearningsopen
Figures in the filing · each found in the filing text
| Net sales · Q3-2026 | $1.07B | +1% y/y |
| Net income · Q3-2026 | $433M | +340% y/y |
| Diluted earnings per share · Q3-2026 | $2.24 | +357% y/y |
| Gross margin · Q3-2026 | 66.8% | |
| Operating cash flow · 9M-2026 | $785M | +43% y/y |
| CooperVision revenue · CooperVision · Q3-2026 | $717M | -0% y/y |
| CooperSurgical revenue · CooperSurgical · Q3-2026 | $349M | +2% y/y |
| Free cash flow · 9M-2026 | $528M | +93% y/y |
Risks flagged
Litigation liability from product recall
“For the nine months ended July 31, 2026, the net impact to the consolidated statements of operations to resolve outstanding claims was $272.0 million, consisting of $325.8 million accrued litigation liability, partially offset by $53.8 million of insurance recoveries” · word for word
HMRC payroll tax dispute
“Depending on the results of the appeal, the Company could prevail on some or all of the issues in dispute, which could result in an obligation to pay a portion or all of the assessed amounts, with an estimated loss ranging from £0 to £71.7 million, plus accrued interest.” · word for word
9 Sep 20268-K · 2.02, 8.01CooperCompanies completed strategic review, increased share repurchase authorization from $2B to $3B, with ~$1.5B remaining. Q3 FY2026 revenue $1.066B (+1% y/y), non-GAAP EPS $1.15 (+4%), free cash flow $273M (+66%). Guidance updated: FY202open
Figures in the filing · each found in the filing text
| Revenue · total · Q3-2026 | $1.07B | +1% y/y |
| GAAP diluted EPS · total · Q3-2026 | $2.24 | +357% y/y |
| Non-GAAP diluted EPS · total · Q3-2026 | $1.15 | +4% y/y |
| Free cash flow · total · Q3-2026 | $273M | +66% y/y |
| Operating cash flow · total · Q3-2026 | $342M | |
| Capital expenditures · total · Q3-2026 | $69M | |
| Gross margin · total · Q3-2026 | 67.0% | |
| Non-GAAP gross margin · total · Q3-2026 | 67.0% | |
| Operating margin · total · Q3-2026 | 21.0% | |
| Non-GAAP operating margin · total · Q3-2026 | 26.0% |
Guidance
FY2026 total revenue $4.229-4.252B (organic 2-3%); CVI $2.828-2.842B (organic 1-2%); CSI $1.401-1.410B (organic 4-5%); FY2026 non-GAAP diluted EPS $4.51-4.55; Q4 FY2026 total revenue $1.057-1.080B (organic 0-2%); CVI $692-706M (organic -2% to 0%); CSI $364-374M (organic 4-6%); Q4 non-GAAP diluted EPS $1.05-1.09
Guidance updated: FY2026 revenue and EPS ranges provided; Q4 CVI organic growth expected -2% to 0% reflecting US channel inventory headwinds; CSI organic growth 4-6% remains solid; overall demand mixed but management tone positive on strategic review completion and cash generation
Risks flagged
CooperVision US channel inventory reduction weighing on results and expected to continue into Q4
“At CooperVision, however, we proactively reduced U.S. channel inventory that weighed on our results and will continue to impact Q4” · word for word
Unfavorable foreign exchange impacting gross margin and operating margin
“non-GAAP gross margin down 60bps driven by higher manufacturing costs and unfavorable foreign exchange; operating margin partially offset by unfavorable foreign exchange”
Higher manufacturing costs pressuring gross margin
“non-GAAP gross margin down 60bps driven by higher manufacturing costs and unfavorable foreign exchange”
5 Jun 202610-QNet sales $1.08B (+8% y/y); Net income (loss) $-78M; Diluted earnings (loss) per share $-0.40open
Figures in the filing · each found in the filing text
| Net sales · Total · Q2-2026 | $1.08B | +8% y/y |
| Net income (loss) · Q2-2026 | $-78M | |
| Diluted earnings (loss) per share · Q2-2026 | $-0.40 | |
| CooperVision net sales · CooperVision · Q2-2026 | $724M | +8% y/y |
| CooperSurgical net sales · CooperSurgical · Q2-2026 | $358M | +8% y/y |
| CooperVision operating income · CooperVision · Q2-2026 | $216M | +16% y/y |
| CooperSurgical operating income (loss) · CooperSurgical · Q2-2026 | $-225M | |
| Operating cash flow · H1-2026 | $444M | +55% y/y |
| Capital expenditures · H1-2026 | $189M | +13% y/y |
| Share repurchases · H1-2026 | $108M | +166% y/y |
Risks flagged
Embryo culture media litigation
“The net impact to the consolidated statements of operations to resolve outstanding claims was $271.6 million, consisting of $324.1 million accrued litigation liability, partially offset by $52.5 million of insurance recoveries.” · word for word
HMRC tax dispute
“estimated loss ranging from £0 to £71.7 million, plus accrued interest” · word for word
Tariff and trade barrier risk
“These risks include ... escalating global trade barriers and disruptions, such as the impact of tariffs.”
Asia Pacific revenue softness
“Asia Pacific 130.6 138.6 (6)%” · word for word
4 Jun 20268-K · 2.02, 8.01Revenue $1.08B (+8% y/y); GAAP diluted EPS $-0.40; Non-GAAP diluted EPS $1.21 (+26% y/y)earningsopen
Figures in the filing · each found in the filing text
| Revenue · total · Q2-2026 | $1.08B | +8% y/y |
| GAAP diluted EPS · total · Q2-2026 | $-0.40 | |
| Non-GAAP diluted EPS · total · Q2-2026 | $1.21 | +26% y/y |
| Gross margin · total · Q2-2026 | 68.0% | |
| Operating margin (GAAP) · total · Q2-2026 | -3.0% | |
| Non-GAAP operating margin · total · Q2-2026 | 27.0% | |
| Interest expense · total · Q2-2026 | $21M | -14% y/y |
| Cash provided by operations · total · Q2-2026 | $183M | |
| Capital expenditures · total · Q2-2026 | $86M | |
| Free cash flow · total · Q2-2026 | $96M |
Risks flagged
Product recall litigation risk largely resolved with >95% claims settled, but $271.6M charge impacts GAAP earnings and cash flow.
“The net impact to the consolidated statements of operations to resolve outstanding claims was $271.6 million... The Company currently expects the majority of the payments to be made during fiscal 2026.” · word for word
6 Mar 202610-QCooper Companies reported Q1 FY2026 revenue of $1.024B (+6.2% YoY) and EPS of $0.66 (+26.9% YoY), with strong operating cash flow and segment margin expansion.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $1.02B | +6% y/y |
| Net income · Q1-2026 | $131M | +25% y/y |
| Diluted earnings per share · Q1-2026 | $0.66 | +27% y/y |
| Gross margin · Q1-2026 | 68.0% | |
| Operating cash flow · Q1-2026 | $261M | +37% y/y |
| Free cash flow · Q1-2026 | $158M | +68% y/y |
| CooperVision net sales · CooperVision · Q1-2026 | $695M | +8% y/y |
| CooperSurgical net sales · CooperSurgical · Q1-2026 | $329M | +3% y/y |
Risks flagged
UK Tax Dispute
“Estimated loss ranging from £0 to £71.7 million, plus accrued interest, related to HMRC payroll tax dispute.” · word for word
Foreign Exchange Exposure
“A uniform hypothetical 10% increase or decrease in foreign currency exchange rates would result in a corresponding increase or decrease of approximately $34.9 million in operating income.” · word for word
5 Mar 20268-K · 2.02Revenue $1.02B (+6% y/y); GAAP Diluted EPS $0.66 (+27% y/y); Non-GAAP Diluted EPS $1.10 (+20% y/y); Guidance: Non-GAAP EPS $4.58-$4.66; FCF $600-$625Mearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $1.02B | +6% y/y |
| GAAP Diluted EPS · Q1-2026 | $0.66 | +27% y/y |
| Non-GAAP Diluted EPS · Q1-2026 | $1.10 | +20% y/y |
| Free Cash Flow · Q1-2026 | $159M | |
| CooperVision Revenue · CooperVision · Q1-2026 | $695M | +8% y/y |
| CooperSurgical Revenue · CooperSurgical · Q1-2026 | $329M | +3% y/y |
| Gross Margin · Q1-2026 | 68.0% | |
| Non-GAAP Operating Margin · Q1-2026 | 27.0% | |
| Share Repurchases · Q1-2026 | $93M |
Guidance
Non-GAAP EPS $4.58-$4.66; FCF $600-$625M
Raised FY2026 non-GAAP EPS and free cash flow guidance based on strong Q1 results and positive outlook.
Risks flagged
Tariff impact on gross margin; excluding tariffs, gross margin would have been flat YoY.
“Excluding the impact of tariffs, gross margin would have been flat year over year.” · word for word
24 Feb 2026DEF 14AProxy statement filed for annual shareholder meeting, detailing executive compensation, governance, and fiscal 2025 performance.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $4.09B | +5% y/y |
| Non-GAAP Diluted EPS · FY2025 | $4.13 | +12% y/y |
| Free Cash Flow · FY2025 | $434M | |
| GAAP Gross Margin · FY2025 | 66.0% | |
| Non-GAAP Gross Margin · FY2025 | 68.0% | |
| GAAP Operating Margin · FY2025 | 17.0% | |
| Non-GAAP Operating Margin · FY2025 | 26.0% | |
| CooperVision Revenue · CooperVision · FY2025 | $2.74B | +5% y/y |
| CooperSurgical Revenue · CooperSurgical · FY2025 | $1.35B | +5% y/y |
| Share Repurchases · FY2025 | $290M |
Guidance
Long-term free cash flow target raised to $2.2B+ through fiscal 2028; buyback authorization expanded to $2B
Management raised long-term free cash flow target and expanded buyback, signaling confidence in future cash generation.
Risks flagged
Restructuring execution risk
“During the fourth quarter of fiscal 2025, the Company completed significant reorganization and integration activity.” · word for word
High capex burden
“capital expenditures of $362.4 million” · word for word
23 Dec 20258-K · 1.01, 5.02, 7.01Entered a material definitive agreement (acquisition, partnership, or major contract); reported the departure of a director or principal officer (CEO/CFO change)open
Risks flagged
Activist involvement may lead to strategic shifts or pressure for operational changes, but cooperation agreement reduces near-term disruption risk.
“Browning West agreed to standstill restrictions and voting commitments through 2027 annual meeting period.”
5 Dec 202510-KRevenue $4.09B (+5% y/y); Operating Cash Flow $796M (+12% y/y); Gross Margin 66open
Figures in the filing · each found in the filing text
| Revenue · Consolidated · FY2025 | $4.09B | +5% y/y |
| Operating Cash Flow · Consolidated · FY2025 | $796M | +12% y/y |
| Gross Margin · Consolidated · FY2025 | 66.0% | |
| CooperVision Revenue · CooperVision · FY2025 | $2.74B | +5% y/y |
| CooperSurgical Revenue · CooperSurgical · FY2025 | $1.35B | +5% y/y |
| Americas Revenue · CooperVision Americas · FY2025 | $1.12B | +5% y/y |
| EMEA Revenue · CooperVision EMEA · FY2025 | $1.06B | +8% y/y |
| Asia Pacific Revenue · CooperVision Asia Pacific · FY2025 | $555M | 0% y/y |
Risks flagged
Regulatory risk for genetic testing
“Increased regulatory scrutiny of genetic testing may adversely affect our business through increased costs and risks associated with gaining marketing approvals or certifications and potential impact on demand for our genetic testing services.” · word for word
Currency exposure
“Our most significant currency exposures are the British pound, Euro and Japanese yen.” · word for word
Debt covenant risk
“Our credit facilities contain financial and other restrictive covenants that could limit our ability to engage in activities that may be in our long-term best interests.” · word for word
4 Dec 20258-K · 2.02, 5.02, 7.01Revenue $1.07B (+5% y/y); Non-GAAP diluted EPS $1.15 (+11% y/y); GAAP diluted EPS $0.43 (-27% y/y); Guidance: Free cash flow >$2.2B cumulative 2026-2028earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $1.07B | +5% y/y |
| Non-GAAP diluted EPS · Q4-2025 | $1.15 | +11% y/y |
| GAAP diluted EPS · Q4-2025 | $0.43 | -27% y/y |
| Free cash flow · Q4-2025 | $150M | |
| CooperVision revenue · CooperVision · Q4-2025 | $710M | +5% y/y |
| CooperSurgical revenue · CooperSurgical · Q4-2025 | $356M | +4% y/y |
| Non-GAAP gross margin · Q4-2025 | 66.0% | |
| Non-GAAP operating margin · Q4-2025 | 27.0% | |
| MiSight revenue growth · CooperVision · Q4-2025 | 37.0% |
Guidance
Free cash flow >$2.2B cumulative 2026-2028
Raised FCF guidance; earnings beat; positive outlook for 2026.
Risks flagged
GAAP EPS down 27% due to reorganization costs; gross margin pressure from tariffs and mix.
“GAAP diluted EPS of $0.43, down 27%... Non-GAAP gross margin was down 70 basis points... primarily from tariffs and mix.”
The Cooper Companies, Inc. — questions
- What did The Cooper Companies, Inc. file recently?
- 13 SEC filings in the last 12 months. Latest: 10-Q on 2026-09-09 — The Cooper Companies reported Q3 2026 results with net income of $432.8M (diluted EPS $2.24) vs $98.3M ($0.49) in prior year, driven by a $307.2M discrete tax benefit and improved operating performance, partially offset by a $272.0M litigat
Every figure on this page comes from The Cooper Companies, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.